Physician profile
Reenal Patel
NPI 1750777447
$22,870.09
in general payments reported to CMS, 2019-2025
35 companies · $3,908 in 2025
The $3,908 reported for 2025 was more than what 90% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $427 · 2020: $553 · 2021: $457 · 2022: $1,191 · 2023: $6,980 · 2024: $9,354 · 2025: $3,908.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $18K · Food and Beverage: $2,472 · Travel and Lodging: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $17,569.61 |
| Food and Beverage | $2,471.91 |
| Travel and Lodging | $199.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $18,326.47 | 2023-2025 | Dupixent |
| Abbott Laboratories | $771.21 | 2019-2023 | Dragonfly Opstar |
| Edwards Lifesciences Corporation | $622.18 | 2022-2025 | Evoque, Sapien 3 Ultra Resilia, Pascal |
| Pfizer INC. | $455.92 | 2019-2025 | |
| Boston Scientific Corporation | $326.06 | 2023-2025 | Watchman Flx, Watchman, General - Therapies |
| Novartis Pharmaceuticals Corporation | $317.59 | 2020-2025 | |
| Amgen INC. | $247.34 | 2019-2024 | Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $232.06 | 2019-2022 | |
| Shockwave Medical, INC | $173.22 | 2024 | Shockwave Intravascular Lithotripsy (Ivl) System With The Shockwave C2+ Coronary |
| Heartflow, INC. | $171.90 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $168.12 | 2021-2024 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.00 | 2022 | |
| Abiomed | $110.17 | 2022-2023 | Impella |
| Glaxosmithkline, LLC. | $92.19 | 2020-2024 | Trelegy Ellipta |
| Inari Medical, INC. | $79.53 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $77.75 | 2020-2025 | Eliquis, Camzyos |
| Cordis US Corp. | $69.63 | 2022 | |
| Janssen Pharmaceuticals, INC | $61.04 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $57.87 | 2023 | Verquvo |
| Philips North America LLC | $51.94 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $48.26 | 2025 | |
| Cardiovascular Systems INC. | $33.13 | 2019-2020 | |
| Biosense Webster, INC. | $31.02 | 2020 | |
| Novo Nordisk INC | $30.53 | 2023 | Ozempic, Rybelsus |
| Terumo Medical Corporation | $22.58 | 2021 | |
| Medtronic, INC. | $22.33 | 2021 | |
| Cvrx, INC. | $21.20 | 2024 | Barostim Neo System |
| Bridgebio Pharma, INC. | $18.30 | 2025 | Attruby |
| Medtronic Vascular, INC. | $17.77 | 2020 | |
| Atricure, INC. | $17.69 | 2023 | |
| Cardinal Health 200 LLC | $16.55 | 2020 | |
| Kiniksa Pharmaceuticals International, Plc | $15.37 | 2024 | Arcalyst |
| Arcutis Biotherapeutics, INC. | $13.68 | 2024 | Zoryve |
| Scpharmaceuticals INC. | $13.12 | 2024 | |
| Avanir Pharmaceuticals, INC. | $11.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reenal Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.